Hence, targeting NO-cGMP signaling could be a new therapeutic strategy for the treatment of PCa related to the TMPRSS2-ERG gene fusion and might be of interest in preclinical and clinical PCa studies. Here, TMPRSS2 is linked to posterior cortical atrophy.